Cite
Anderson A, Matsumoto M, Secrest A, et al. Cost of Treatment of Benign and Premalignant Lesions During Skin Cancer Screening. JAMA Dermatol. 2021;157(7):876-879doi: 10.1001/jamadermatol.2021.1953.
Anderson, A., Matsumoto, M., Secrest, A., Saul, M. I., Ho, J., & Ferris, L. K. (2021). Cost of Treatment of Benign and Premalignant Lesions During Skin Cancer Screening. JAMA dermatology, 157(7), 876-879. https://doi.org/10.1001/jamadermatol.2021.1953
Anderson, Alyce, et al. "Cost of Treatment of Benign and Premalignant Lesions During Skin Cancer Screening." JAMA dermatology vol. 157,7 (2021): 876-879. doi: https://doi.org/10.1001/jamadermatol.2021.1953
Anderson A, Matsumoto M, Secrest A, Saul MI, Ho J, Ferris LK. Cost of Treatment of Benign and Premalignant Lesions During Skin Cancer Screening. JAMA Dermatol. 2021 Jul 01;157(7):876-879. doi: 10.1001/jamadermatol.2021.1953. PMID: 34106213; PMCID: PMC8190700.
Copy
Download .nbib